Free Republic

VIDEO In late 2021, Pfizer and its paid lackeys in the media and government were in panic mode. Vaccine skepticism had already set in and Ivermectin was proving to be a safe, effective, and inexpensive treatment. In addition, almost NOBODY believed the propaganda the Pfizer-paid media (especially by Joe Rogan hating CNN) hurled against Ivermectin. So what happened? Pfizer came up with its own answer to Ivermectin, Paxlovid, which not only had multiple side-effects but at over $1300 for a five day course was much more expensive than a very safe Ivermectin which cost only about $30 for 20 3...

Tens of thousands of Americans are hospitalized with COVID-19 every week. Thousands die from it every month. And yet, an antiviral treatment proven to lessen the chances of severe outcomes is going underused. The drug, Paxlovid, is lauded by experts as a powerful tool that can prevent hospitalization and death from COVID-19. But the high price and doctors’ hesitation to prescribe the pills mean the five-day treatment isn’t getting to everyone who would benefit from it. “When you read in your local newspaper that in this hospital, they’ve got this many COVID patients, most of those are preventable hospitalizations,” said...

Asmall and preliminary study published Monday seems to indicate that patients receiving the drug Paxlovid are far more likely to experience Covid rebound than those who did not take it. That conclusion runs counter to previous statements by Pfizer, which makes Paxlovid, and by researchers at the Food and Drug Administration who have argued that while it is not uncommon for people with Covid to have symptoms reemerge after they seem to have recovered, it is not clear that Paxlovid increases the risk of this occurring.

Pfizer reported a third-quarter loss during Tuesday’s earnings call as the demand for its COVID-19 vaccines and one popular antiviral medication to treat the virus decreased substantially, according to CNBC. The pharmaceutical giant announced it recorded a write-off of $5.6 billion due to the drug Paxlovid and its vaccine, Comirnaty. Paxlovid lost the company $4.7 billion, while the mRNA vaccine was responsible for $900 million in losses. The company reported a quarterly revenue of $13.2 billion, which was down 42 percent from 2022’s second quarter. According to CNBC, Pfizer’s COVID shots generated $1.31 billion in revenue from July to September....

CNN — The price of the lifesaving Covid-19 antiviral medication Paxlovid will more than double as the United States transitions out of the emergency phase of the pandemic, drugmaker Pfizer said Wednesday. The list price, before insurance, will be $1,390 for a five-day course, Pfizer said in a statement. That’s 2.6 times higher than the $530-per-course price paid by the US government, which provided Paxlovid free to patients during the pandemic. The Wall Street Journal first reported the new price.

Pfizer has slashed its sales estimates for COVID antiviral Paxlovid by $7 billion and its COVID vaccine Comirnaty by $2 billion. It adds up to a 13% decline in projected revenue for the company in 2023. As the coronavirus outbreak has shifted to the endemic phase, drugmakers have warned of a drop in demand for COVID-19 products, with the impact coming into focus during the fall vaccination season. Pfizer has stepped up to the plate with an update, and its effects are staggering as the company has slashed its 2023 revenue projection by $9 billion. Pfizer now expects sales to...

The CDC found itself hoist with its own petard by making 25 basic statistical and numerical errors related to COVID-19, particularly with regard to children, while purporting to expose COVID vaccine misinformation, according to an analysis led by University of California San Francisco epidemiologists. The preprint, which has not yet been peer-reviewed, documented 20 errors that "exaggerated the severity of the COVID-19 situation" and three that "simultaneously exaggerated and downplayed" severity, while one each was neutral or exaggerated vaccine risks. More than half were from 2022, but nearly as many were made in the first two months of 2023 as...

Vaccines chief may have been cut out of White House-Pfizer loop on early trial data for Omicron-targeting booster, recalling White House making original booster decision. The FDA is getting feisty as a cascade of early research on the effectiveness of COVID-19 bivalent boosters, which were authorized without human data, intersects with embarrassing headlines about "rebound" infections for highly inoculated federal officials. Public health officials stand to get even more defensive amid revelations that Pfizer is sharing undisclosed booster efficacy data with the White House and that boosters may actually weaken immune systems' ability to fight COVID. Center for Biologics Evaluation...

A recent preprint study found that Pfizer’s COVID-19 antiviral Paxlovid may be effective in reducing the risk of developing long COVID in patients recovering from coronavirus infections. The study, funded by the Department of Veterans Affairs (VA), looked through the VA’s health care databases and identified individuals who tested positive for COVID-19 between March and June 2022. Overall, 56,340 participants were included in the study, among whom 9,217 were given Paxlovid within five days of testing positive for SARS-CoV-2, while the remaining 47,123 did not receive any form of COVID-19 antiviral or antibody treatment in the 30 days after their...

Rochelle Walensky, director of the Centers for Disease Control and Prevention (CDC), has tested positive for COVID-19 again after completing a round of the coronavirus antiviral treatment Paxlovid. Walensky tested positive for COVID-19 earlier this month, going into isolation and taking “appropriate action” for her health. On Monday, the CDC said Walensky had experienced “mild symptoms” during her infection and eventually tested negative for the virus after completing a round of Paxlovid. “On Sunday, Dr. Walensky began to develop mild symptoms and has again tested positive. Consistent with CDC guidelines, she is isolating at home and will participate in her...

CNN — People of color – especially Black and Hispanic people – were less likely to receive Paxlovid and other Covid-19 treatments, according to a study published Thursday by the US Centers for Disease Control and Prevention. Throughout the pandemic, Black and Hispanic people have been about two times more likely than White people to be hospitalized or die from Covid-19. The new study showed Black Covid-19 patients were 36% less likely than White patients to be treated with Paxlovid, and Hispanic patients were 30% less likely than non-Hispanic patients to receive the antiviral pill. Nearly one in three White...

Covid-19 patients with a history of cardiovascular disease are at an increased risk of developing severe illness and could benefit most from the Covid-19 treatment Paxlovid – but there’s a catch. Paxlovid can have dangerous interactions with some of the most common medications for cardiovascular disease, including certain statins and heart failure therapies, a new paper warns. The review paper, published Wednesday in the Journal of the American College of Cardiology, lists dozens of cardiovascular medications and whether they are safe to give along with Paxlovid or whether they could have interactions. Some medications such as aspirin are safe to...

Pfizer's COVID-19 pill appears to provide little or no benefit for younger adults, while still reducing the risk of hospitalisation and death for high-risk seniors, according to a large study published on Wednesday (Aug 24). The results from a 109,000-patient Israeli study are likely to renew questions about the US government's use of Paxlovid, which has become the go-to treatment for COVID-19 due to its at-home convenience. The Biden administration has spent more than US$10 billion purchasing the drug and making it available at thousands of pharmacies through its test-and-treat initiative. The researchers found that Paxlovid reduced hospitalisations among people...

First Lady Jill Biden has caught a rebound case of COVID-19, just three days after leaving quarantine. Biden tested positive again Wednesday, her office announced, but she’s not showing any symptoms. She will stay in Delaware in isolation until she clears protocols again.

First lady Jill Biden tested positive for COVID-19 on Wednesday in a "rebound" case, her office said. Jill Biden, who is double vaccinated and twice boosted, was prescribed the antiviral treatment Paxlovid, which President Biden also took after testing positive last month. Like his wife, the president also suffered a rebound COVID-19 case.

President Joe Biden flouted coronavirus mask protocols on Tuesday after his wife Jill Biden tested positive for the virus. The president was spotted removing his mask to deliver a speech and immediately coughed into his hand after shaking hands with Sen. Chuck Schumer.

First lady Dr. Jill Biden has tested positive for Covid-19 and is experiencing mild symptoms, her spokesperson said Tuesday. The first lady, who is double vaccinated and twice boosted, is taking Paxlovid, Pfizer’s antiviral drug, per Alexander.

President Biden continues to harbor the COVID-19 virus (SARS-CoV-2) in his body. He first contracted COVID-19 on July 21, two and a half weeks before the present. Is this because of immunosuppression - due to his heavily boosted status, or for some other reason? That being said, the single antiviral drug regime of Paxlovid may also be causing the virus to stay in his body for a long time, an effect otherwise referred to as “the rebound” effect:“The hypothesis is that the immune system didn’t have a chance to see the full extent of the virus, since Paxlovid suppressed replication...

President Joe Biden continued to test positive for COVID-19 Tuesday but is feeling "well," according to a memo from Dr. Kevin O'Connor, Biden's physician. "The President continues to feel well, though he is experiencing a bit of a return of a loose cough. He remains fever-free and in good spirits. His temperature, pulse, blood pressure, respiratory rate and oxygen saturation remain entirely normal. His lungs are clear," O'Connor wrote. O'Connor added that Biden "will continue his strict isolation measures" and "will continue to conduct the business of the American people from the Executive Residence." Biden initially tested positive for COVID-19...

When Paxlovid came to market in December 2021, studies from Pfizer indicated that only 1-2 percent of patients who took the drug tested positive for Covid again shortly after finishing their dosage.But other experts say the rapid reinfection rate is closer to 40 per cent, and that Paxlovid can cause this issue by suppressing patients’ immune systems too early, meaning their own bodies are unable to get a handle on COVID.Dr. Jonathan Reiner, a prominent cardiologist and professor of medicine and surgery at George Washington University Hospital tweeted: ‘I think this was predictable.’He continued: ‘The prior data suggesting ‘rebound’ Paxlovid...